New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
11:02 EDTALXNAlexion:Data show substantial improvement with Soliris in patients with STEC-HUS
Alexion Pharmaceuticals announced the presentation of 28-week data from all enrolled patients in a multi-center trial of eculizumab, Soliris, in patients who developed Shiga-toxin-producing E. coli hemolytic uremic syndrome, STEC-HUS, during an outbreak in Germany from May 2011 to July 2011. In the study, eculizumab therapy was associated with rapid and sustained clinical improvements in thrombotic microangiopathy, TMA, and systemic organ complications. The study met its primary endpoint of global assessment of efficacy at 8 weeks with 94% of patients achieving a complete or partial response in systemic TMA and vital organ involvement. Key secondary endpoints were also met with high clinical and statistical significance, including global assessment of efficacy at 28 weeks as well as improvement in hematologic, renal and neurologic functions. Preliminary findings from an exploratory post hoc, matched-control analysis of patients with severe STEC-HUS receiving eculizumab versus other patients who received current best supportive care during the German epidemic were also reported, and showed that eculizumab treatment was associated with consistently higher rates of renal and neurological function improvement at weeks 8 and 28.1
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
06:35 EDTALXNAlexion's Soliris granted ODD in Japan
Alexion Pharmaceuticals announced that Soliris, or eculizumab, has been granted orphan drug designation, or ODD, by Japanís Ministry of Health, Labour and Welfare for the treatment of patients with neuromyelitis optica, or NMO, a life-threatening, ultra-rare neurologic disorder. In patients with NMO, chronic, uncontrolled complement activation results in severe damage to the central nervous system, predominantly impacting the optic nerve and spinal cord.1-3 This devastating disease is characterized by severe weakness, paralysis, respiratory failure, loss of bowel and bladder function, blindness and premature death.4-6
November 20, 2014
07:09 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 19, 2014
10:28 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 18, 2014
07:52 EDTALXNFDA Drug Safety & Risk Management Advisory Committee to hold a meeting
The Committee discusses the risk management of Alexion Pharmaceuticals' Eculizumab (Soliris) is a meeting being held at FDA Silver Spring, Maryland offices on November 18 at 9 am. Webcast Link
November 16, 2014
13:04 EDTALXNAlexion says data supports effectiveness of sustained Soliris treatment in aHUS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use